Document is current
Any future updates will be listed below
-
Authors
MacDonald, Julie A. https://orcid.org/0000-0001-9288-2722
Bradshaw, Gary A.
Jochems, Fleur
Bernards, René https://orcid.org/0000-0001-8677-3423
Letai, Anthony https://orcid.org/0000-0002-1993-9013
-
Funding
Funding for this research was provided by:
The authors gratefully acknowledge support from the Mark Foundation for Cancer Research via an Aspire Award to the Letai and Bernards Laboratories
- License Information
-
More Information
Article History
Received: 14 June 2024
Revised: 20 November 2024
Accepted: 4 December 2024
First Online: 6 January 2025
Competing interests
: JAM, GAB, and FJ declare no competing interests. RB discloses he is the co-founder of Oncosence BV, Chief Scientific Officer at Agendia Inc., and board member of Lixte Biotechnology Holdings, Inc. AL discloses that he is on the Scientific Advisory Boards of Zentalis Pharmaceuticals and Flash Therapeutics.
